Heart failure & cardiomyopathies
Systematic Review of Sodium-Glucose Cotransporter 2 Inhibitors: A Hopeful Prospect in Tackling Heart Failure-Related Events
Authors' conclusion
Their beneficial effects on HF, especially in left ventricular dysfunction, have made their use possible irrespective of diabetes mellitus or atrial fibrillation status.
Study context
- Population
- Patients in randomized controlled trials (RCTs) of SGLT2 inhibitors in heart failure (HF)
- Participants
- 83,878 patients · 12 RCTs
- Comparison
- SGLT2 inhibitors vs control
- Outcome
- AF, HF hospitalisation, CV death and MACE (pooled)
Methodological details1139 records identified, Searches of PubMed/Medline, CENTRAL and ClinicalTrials.gov; no date or publication-status restrictions; language restrictions
- 1139 records identified
- Searches of PubMed/Medline, CENTRAL and ClinicalTrials.gov; no date or publication-status restrictions; language restrictions
Pooled result
As reported in the abstract
SGLT2 inhibitorsOdds ratio (95% CI)
AF; PI: 0.57-1.19
0.83(0.68–1.01)
HF hospitalisation; PI: 0.60-0.78
0.69(0.60–0.78)
CV death; PI: 0.42-1.60
0.82(0.58–1.15)
MACE; PI: 0.71-1.15
0.90(0.77–1.06)
Further pooled results
- SGLT2 inhibitors significantly improve quality of life in HF patients
Original publication
Systematic Review of Sodium-Glucose Cotransporter 2 Inhibitors: A Hopeful Prospect in Tackling Heart Failure-Related Events. ESC Heart Fail. Published 26 March 2023. doi:10.
Summarised from the published abstract; every number is checked against it